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Abstract
Background: Hypothyroidism in pregnancy is an arena of ongoing research, with international conflicts regarding
screening, management, and outcomes. Various studies have described the outcomes depending on geographical
and international diagnostic criteria. No study has been conducted in this regard from the region of Pakistan.
Therefore, we aim to report the clinical features and maternal outcomes of hypothyroid pregnancies and compare
the maternal outcomes between uncontrolled and controlled TSH levels in the preconception as well as the
gestational period.
Methods: We conducted a cross-sectional retrospective study on 718 cases in the Aga Khan University Hospital
after ethical approval. We collected information on pregnant females who have diagnosed hypothyroidism before
conception or during their antenatal period. We noted the maternal characteristics and maternal comorbidities.
Laboratory data were recorded for thyroid stimulating hormone levels before conception and during gestation. We
recorded maternal outcomes as pregnancy loss (including miscarriage, stillbirth/intrauterine death, medical
termination of pregnancy and ectopic pregnancy), gestational hypertension, pre-eclampsia, postpartum
hemorrhage, placental abruption, and modalities of delivery. Data analysis was performed on Statistical Package for
the Social Sciences version 20.0.
Results: Among 708 hypothyroid women 638 had live births. Postpartum hemorrhage was the most frequent
maternal outcome (38.8%). The emergency cesarean section occurred in 23.4% of cases. We determined TSH levels
in 53.2, 56.7, 61.7 and 66.6% of cases in preconception, 1st, 2nd, and 3rd trimester periods. A significant association
existed between cesarean section and preconception thyrotropin levels > 2.5 mIU/L, whereas postpartum
hemorrhage was significantly associated with thyrotropin levels > 2.5 mIU/L in the preconception and third
trimester.
Conclusion: Successful live births in our patients were complicated by maternal postpartum hemorrhage and a
frequent number of emergency cesarean section.
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Background
One of the commonest endocrine disorders in women of
reproductive age is hypothyroidism, which often presents
as an inter-current disease during pregnancy and in the
puerperium. Similar to the non-pregnant state; overt
hypothyroidism in pregnancy is also defined as increased
serum thyroid stimulating hormone (TSH) and decreased
serum free thyroxine (FT4), which ranges in prevalence
from 0.3–3% of pregnancies in western world [1–3],
whereas recent studies from some countries of the Asian
subcontinent have reported a higher but variable preva-
lence of 4.8% to up to 13.13% [4–7].
On the other hand, subclinical hypothyroidism (without
typical symptoms of hypothyroidism, increased TSH and
normal thyroid hormone levels), has an estimated preva-
lence of 2–5% of all cases reported in the literature [3, 8, 9].
There are several obstetric complications associated with
hypothyroidism in pregnancy like gestational hypertension
and miscarriages [10–12]. As thyroid hormones have many
effects on cardiovascular physiology and blood pressure
regulation, there is a higher prevalence of gestational hyper-
tension compared to euthyroid women [13–17]. Moreover,
inadequate thyroid hormone levels in the mother have also
been associated with low birth weight and fetal death or
abortions [12, 18]. Nevertheless, data in the past have sug-
gested impaired neurocognitive development in fetuses and
children of hypothyroid and euthyroid antibody-positive
mothers [2, 19, 20], but recent trials have shown no benefit
of treatment on the outcomes [21–23]. Maternal thyroid
hormones also have a significant physiological role in early
placental development by regulating human trophoblast
proliferation and invasion [3, 8, 9, 19, 20]. Inadequate
trophoblast cell invasion may result in abnormal placenta-
tion (which is a notable risk factor for preterm delivery)
[24–28] and placental abruption which can also lead to
stillbirth [14]. Moreover, euthyroid women with auto-
immune thyroid disease show impaired thyroid function
during gestation and seem to suffer from a high rate of ob-
stetrical complications [29]. Finally, populations’ urinary
iodine excretion cannot be ignored. In 2011, National Nu-
trition Health Survey was conducted in Pakistan, according
to which there is 48% iodine deficiency which has however
improved over the last decade [30].
Thus, hypothyroidism is a serious, yet manageable
medical disorder in pregnancy, and despite significant
evidence of hypothyroid related maternal and neonatal
complications, universal screening is currently not rec-
ommended in pregnant women or women of reproduct-
ive age by various professional societies.
To the best of our knowledge, maternal outcomes of
pregnancies affected by hypothyroidism have never been
reported from Pakistan. Therefore, we aim to report the
clinical features and maternal outcomes of hypothyroid
pregnancies and compare the maternal outcomes between
uncontrolled and controlled TSH levels in the preconcep-
tion as well as the gestational period.
Methods
Study design
We conducted a retrospective chart review of
hypothyroid pregnant patients from their preconception
to complete gestational phase (with whatever outcome),
from 2008 to 2016, presenting to Aga Khan University,
Karachi, Pakistan.
Study setting
The hypothyroid pregnant females presenting to endo-
crine and obstetric clinics at the Aga Khan University
Hospital.
Eligibility criteria
Inclusion criteria We selected patients, according to
the following inclusion criteria:
 All pregnant women attending endocrine and
obstetric clinic who had been diagnosed
hypothyroidism defined as either overt (elevated
TSH and low FT4) or subclinical (elevated TSH and
normal FT4) hypothyroidism and those labeled only
‘hypothyroidism’ (uncategorized) by the clinician
either before or during pregnancy.
 These patients were also on levothyroxine
replacement with doses adjusted appropriately to
aim controlled hypothyroidism with TSH ≤2. 5 uIU/
mL throughout pregnancy [31].
Exclusion criteria Pregnant women who were not diag-
nosed as either overt or subclinical hypothyroidism or
those not labeled ‘hypothyroidism’ were excluded from
the study.
Sample size assumption
The maternal outcomes of pregnancies affected by
hypothyroidism, from literature showed that spontan-
eous abortions were 15.48% [32] in patients with sub-
clinical hypothyroidism. Therefore, taking the frequency
of 16% with a 95% confidence level and a bound on
error of ±6% the estimated sample size was 278 pregnant
women.
Sampling technique
Non-probability consecutive sampling. Purposive sam-
pling was employed.
Data collection
We reviewed the medical record files of pregnant fe-
males from their preconception phase to gestational
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period, during the years 2008–2016. We selected these
females by applying coding words of hypothyroidism
and pregnancy in the electronic medical record main-
tained according to the international classification of dis-
eases (ICD) coding system in the Health Information
and Management System (HIMS) department of our
hospital. Data were collected by trained medical doctors.
It was randomly double-checked and corroborated by
the principal investigator. Data on maternal characteris-
tics included age, weight, height, parity and week(s) of
pregnancy at first visit. We calculated body mass index
from the weight and height taken on first visit, any time
during pregnancy. History of diabetes, hypertension and
smoking status was also noted, and history of
hypothyroidism was detailed as either subclinical, overt
or uncategorized according to the inclusion criteria
stated earlier. Underlying cause of hypothyroidism and
family history of hypothyroidism was noted wherever
stated. Gestational age at delivery, modes of labour and
indications as well as the mode of delivery were noted,
as per records of obstetric clinical pathway maintained
in the files. Finally, we recorded maternal outcomes like
pregnancy loss, gestational hypertension, pre-eclampsia,
postpartum hemorrhage, placental abruption and mode
of delivery for all pregnancies from obstetric discharge
summaries.
Thyroid stimulating hormone levels and thyroid
antibodies
TSH levels available before conception and during each
month throughout pregnancy were noted. TSH levels
were assessed by Advia Centaur (Siemens Diagnostics),
Chemiluminescence immunoassay. Specificity of the
Advia Centaur third generation TSH assay was deter-
mined against hCG (human chorionic gonadotropin),
FSH (follicle-stimulating hormone) & LH (luteinizing
hormone) with no significant cross-reactivity observed.
The functional sensitivity of the assay is 0.008 uIU/mL,
with the reference range from 0.008–150 uIU/mL. Thy-
roid peroxidase (TPO) antibodies were assayed on
Immulite 2000 (Siemens Diagnostics) using Chemilu-
minescence immunoassay technique.
Definitions of maternal outcomes
We defined maternal outcomes as per internationally ac-
cepted criteria.
 Pregnancy loss: [1] Spontaneous Abortion; defined as
loss of pregnancy at or before 20 weeks of gestation.
[2] Intrauterine death (IUD) or stillbirth; defined as
pregnancy loss occurring after 20 weeks of gestation
[33, 34]. Other outcomes include ‘Medical
termination of pregnancy’ (anytime during
pregnancy) and ‘Ectopic pregnancy’ as determined by
the clinician based on obstetric examination and
investigations.
 Gestational hypertension (GH): Women started on
anti-hypertensives during antenatal visits were la-
beled as gestational hypertension, a condition char-
acterized by high blood pressure that develops after
week 20 in pregnancy [35]. Others were labelled as
‘Chronic Hypertension’.
 Pre-eclampsia: Pregnant women characterized by
both high blood pressure (> 140/90 mmHg) and
proteinuria (≥ 0.3 g/24 h) that develops after 20
weeks of gestation in a previously normotensive
woman [36].
 Postpartum Hemorrhage: Defined as a blood loss of
500 ml or more within 24 h after birth [37].
 Placental Abruption: Defined as the separation of
the placenta from uterine lining any time after the
20th week of pregnancy.
 Modes of delivery: These were noted as emergency
or elective cesarean sections, spontaneous vaginal




We performed descriptive analysis for demographic and
clinical features of hypothyroid pregnant women as well
as the maternal outcomes. Results are presented as mean
(with standard deviation) for normally distributed data
and as median (interquartile range) for skewed distribu-
tion of quantitative variables. For qualitative variables,
we used frequency (percentage). We grouped BMI into
underweight (< 18.5), normal (18.5–24.9), overweight
(25–29.9) and obese (> = 30) categories. Age was catego-
rized into different age ranges. Similarly, parity was cate-
gorized into nulliparous and multiparous groups. After
excluding missing TSH values for each trimester and pre
conceptional periods, we analyzed the total number of
patients for baseline characteristics as well as maternal
outcomes. (See Additional file 1 for further details.)
Inferential statistics
We categorized preconception TSH levels into a con-
trolled group (TSH levels ≤2.5 uIU/mL) and uncontrolled
group (TSH levels > 2.5 uIU/mL) as per American Thy-
roid Association (ATA) criteria, and cases with no precon-
ception TSH levels were excluded from the analysis. We
calculated medians of TSH levels in each month for each
trimester and also similarly grouped them. To compare
baseline characteristics as well as maternal outcomes be-
tween preconception and trimester-wise TSH groups, re-
coding of data was performed. Pregnancy outcomes were
grouped as pregnancy loss (including abortion, ectopic
pregnancy, termination of pregnancy and intrauterine
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death or stillbirth) and uneventful pregnancy (live births,
twin and triplet pregnancies). Similarly, the etiology of
hypothyroidism was divided into autoimmune and post-
treatment categories. Univariate analysis of baseline char-
acteristics was performed for preconception TSH groups.
Subgroup analysis of maternal outcomes of pregnancies
affected by uncontrolled hypothyroidism during precon-
ception and trimester-wise gestational periods was
assessed using the Chi-square and Fischer Exact test. Stat-
istical significance was taken as P-value ≤0.05. Data ana-
lysis was performed on Statistical Package for the Social
Sciences version 20.0.
Results
During 2008–2016, a total of 718 cases were retrieved
using the code hypothyroidism and pregnancy out of
which 10 cases were either lost to follow up or delivered
elsewhere. Figure 1 shows groups of hypothyroid pa-
tients analyzed. Six patients had delivered twice during
this period, so 702 hypothyroid patients out of 708 preg-
nancies were included in the study population.
Characteristics of hypothyroid pregnancies and maternal
outcomes
Table 1 summarizes the clinical characteristics of overall
hypothyroid pregnancies. The mean age of the hypothyroid
pregnancies was 31 years (SD 4.73). These women had pre-
sented at various gestational ages in our hospital, the major-
ity presenting in the first trimester (61%) with a maximum
of 9.6% present in the 8th week. Most of the patients were
diagnosed before pregnancy with unknown initial severity
of hypothyroidism, however, there were more subclinical
cases compared to overt hypothyroidism even in those di-
agnosed during pregnancy. Twenty-seven cases did not
classify into either pre conceptional or gestational
hypothyroidism. Three cases with Hashimoto’s also had a
goiter. Family history of hypothyroidism was positive in
15.3% (10.9% in first degree relatives and 3.5% in second-
degree relatives), whereas it was negative in 43% cases. TSH
levels were determined in 53.2, 56.7, 61.7 and 66.6% of
cases in preconception, 1st, 2nd, and 3rd trimester periods
respectively. Median TSH (with interquartile range) before
conception was 2.9 (1.5–5.8), whereas, during first, second
and third trimester, it was 3.0 (1.4–5.4), 2.4 (1.5–3.8) and
2.3 (1.5–3.8) respectively.
A total of 372 pregnancies delivered through cesarean
section (C-section). Out of those who underwent elective
lower segment cesarean section (LSCS), 60.5% did so be-
cause of previous C-section and the rest have appropri-
ate obstetric indications (6.3% fetal growth restriction or
intrauterine growth restriction [IUGR], 4.0% twin preg-
nancy, 3.6% failure to progress amongst others) whereas,
Fig. 1 Flow chart of the study. Number of patients in preconception and gestational hypothyroid groups
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4.0% were due to patient’s request. Twenty-three percent
of pregnancies underwent emergency LSCS (Em-LSCS),
out of which 22.3% were due to non-reassuring cardioto-
cography (CTG), 4.7% due to pre-eclampsia, and 4.1%
due to IUGR amongst others.
In our study population, postpartum hemorrhage
(PPH) was the most frequent maternal outcome (38.8%)
where 61.5% of cases resulted in a PPH blood volume of
500 ml. We found gestational hypertension (11.6%) and
pre-eclampsia (4.1%) to be the next most common ma-
ternal outcomes. The overall pregnancy loss occurred in
70 cases with abortions in 6.5% of pregnancies.
Association between preconception and gestational
(trimester-wise) TSH and baseline characteristics as well
as maternal outcomes
Details of clinical characteristics and maternal outcomes
are described for these patients in Table 2.
We did not find any significant association between base-
line characteristics and preconception TSH groups (Table 3).
Subgroup analysis of maternal outcomes revealed a signifi-
cant association of mode of delivery including cesarean sec-
tion (emergency & elective) and postpartum hemorrhage
with a TSH value of more than 2.5 uIU/mL before preg-
nancy (p values ≤0.05). Similarly, postpartum hemorrhage is
Table 1 Clinical features of overall hypothyroid pregnancies at
Aga Khan University
Clinical characteristics Frequency (%)
N = 708
Age (years)
Age 18–25 87 (12.3)
Age 26–33 403 (56.9)
Age 34–40 200 (28.2)







Body Mass Index (Kg/m2)
Underweight (< 18.5) 19 (2.7)
Normal (18.5–24.9) 177 (25.0)
Overweight (25–29.9) 221 (31.2)
Obesity class I (30–34.9) 150 (21.2)
Obesity class II and above (> = 35) 47 (6.6)
Unknown 94 (13.3)
Gestational age at antenatal visit (weeks of pregnancy) 11 (7–19)




Not applicable (because of caesarian section) 260 (40.8)





SVD with Episiotomy 156 (24.5)
Gestational age at delivery (weeks) 38 (37–39)
Hypothyroidism diagnosed during pregnancy
Uncategorized 14 (2.0)
Overt hypothyroidism 13 (1.8)
Subclinical hypothyroidism 43 (6.1)
Hypothyroidism diagnosed prior to pregnancy
Uncategorized 308 (43.5)
Overt hypothyroidism 86 (12.6)
Subclinical hypothyroidism 217 (30.6)
Neither preconceptional nor Gestational Hypothyroidism 27 (3.8)
Etiology of Hypothyroidism
Hashimoto’s 183 (25.8)
Post Radioactive Iodine ablation 8 (1.1)
Table 1 Clinical features of overall hypothyroid pregnancies at
Aga Khan University (Continued)
Clinical characteristics Frequency (%)
N = 708
Post-surgical 6 (0.8)
Postpartum thyroiditis 4 (0.6)
Secondary Hypothyroidism 1 (0.1)
After medical treatment for Grave’s Disease 2 (0.3)
Congenital 1 (0.1)
Nodular Goiter 2 (0.3)





Not checked 493 (69.6)
Comorbidities (positive cases only)
Diabetes mellitus 55 (7.8)
Gestational diabetes 150 (21.2)
Hypertension
Pregnancy Induced Hypertension 75 (10.6)
Chronic Hypertension 34 (4.8)
Smoking 1 (0.1)
Data are expressed as mean (± standard deviation) or median
(interquartile range)
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Table 2 Clinical features and maternal outcomes of hypothyroid pregnancies who had TSH measured before conception and









CLINICAL CHARACTERISTICS N (%) N = 377 N (%) N = 402 N (%) N = 437 N (%) N = 471
Age (years)
18–25 31 (8.22) 47 (11.7) 57 (13.0) 60 (12.7)
26–33 221 (58.62) 234 (58.2) 253 (57.9) 271 (57.5)
34–40 119 (31.56) 111 (27.6) 121 (27.7) 131 (27.8)
41–47 6 (1.59) 10 (2.5) 6 (1.4) 9 (1.9)
Parity
Nulliparous 96 (25.81) 126 (31.3) 146 (33.4) 147 (31.2)
Multiparous 276 (74.19) 269 (66.9) 285 (65.2) 312 (66.2)
Body Mass Index (Kg/m2)
Underweight (< 18.5) 13 (3.83) 13 (3.2) 16 (3.7) 14 (3.0)
Normal (18.5–24.9) 99 (29.20) 118 (29.4) 124 (28.4) 120 (25.5)
Overweight (25–29.9) 116 (34.22) 124 (30.8) 141 (32.2) 138 (29.3)
Obesity class I (30–34.9) 88 (25.96) 81 (20.1) 95 (21.7) 103 (21.9)
Obesity class II and above (> = 35) 23 (6.78) 28 (7.0) 28 (6.4) 38 (8.1)
Hypothyroidism diagnosed during pregnancy
Yes 15 (4.00) 38 (9.5) 45 (10.3) 46 (9.8)
No 360 (96.00) 361 (89.8) 387 (88.6) 413 (87.7)
Etiology of Hypothyroidism
Autoimmune 362 (96.28) 390 (97.0) 425 (97.3) 457 (97.0)
Post treatmenta 14 (3.72) 12 (3.0) 12 (2.7) 14 (3.0)
Thyroid antibodies
Positive 114 (78.08) 114 (28.4) 115 (26.3) 116 (24.6)
Negative 32 (21.92) 30 (7.5) 42 (9.6) 43 (9.1)
Comorbidities
Diabetes Mellitus
yes 28 (7.43) 34 (8.5) 31 (7.1) 34 (7.2)
no 349 (92.57) 368 (91.5) 406 (92.9) 437 (92.8)
Gestational diabetes mellitus
yes 82 (21.75) 82 (20.4) 99 (22.7) 123 (26.1)
no 295 (78.25) 320 (79.6) 338 (77.3) 348 (73.9)
Hypertension
Normotensive 327 (86.74) 353 (87.8) 366 (83.8) 396 (84.1)
Gestational Hypertension & Chronic
Hypertension
50 (13.26) 49 (12.2) 71 (16.2) 75 (15.9)
MATERNAL OUTCOMES
Mode of labor (for live births only)
Spontaneous 66 (33.00) 75 (18.7) 86 (19.7) 94 (20.0)
Induced 89 (44.50) 84 (20.9) 110 (25.2) 123 (26.1)
Augmented 45 (22.50) 44 (10.9) 55 (12.6) 58 (12.3)
Not applicable due to Caesarean section 145 (38.5) 151 (37.6) 171 (39.1) 195 (41.4)
Mode of delivery (for live births only)
Em-LSCS 73 (19.4) 72 (17.9) 92 (21.1) 109 (23.1)
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also significantly associated with a TSH value of more than
2.5 uIU/mL in the third trimester (p-value 0.03) (Table 4).
However, there is no significant effect of TSH levels during
each trimester on other maternal outcomes, and the median
TSH remained below 2.5 uIU/mL except in the first trimes-
ter only [31, 38].
Discussion
Maternity care is different in rural and urban communi-
ties of Pakistan, where health facility-related births are
limited mostly to urban setup [39]. However access to
such healthcare has overall increased to almost 3.6 times
from 1991 to 2013, but the government goals are still
not achieved [39]. Rural health centers, dispensaries,
basic health units, and the lady health worker program
in Pakistan has allowed more home-based deliveries as
compared to health facility births in less privileged areas
[40]. This can be one reason why all hypothyroid preg-
nant women do not consider antenatal care or rather
never access a tertiary hospital. Although, majority of
pregnant women in our study were diagnosed with
hypothyroidism before conception (89.7%), even then
the number of TSH assays performed was less in our co-
hort (53.2, 56.7, 61.7 and 66.6% of cases in preconcep-
tion, 1st, 2nd, and 3rd trimester periods), in contrast to
a Scottish study [41]. Although the etiology of
hypothyroidism remained unknown in the majority of
cases, we found that the most common cause of
hypothyroidism was autoimmune thyroiditis in our
population which is in accordance with a similar study
reported in the literature [42]. Other causes included
radioiodine ablation, post-surgical hypothyroidism, and
postpartum thyroiditis. Our study found 22.3% of the
women to be anti-TPO positive amongst hypothyroid
pregnancies. The presence of thyroid anti-TPO anti-
bodies were found positive in 40% of hypothyroid preg-
nant females in one of the epidemiological study [7],
while another study reported 57.1% in subclinical
hypothyroid cases [43]. Whether all women should be
checked for autoimmunity once diagnosed with
hypothyroidism remains an understudied area.
Data regarding maternal comorbidities affecting
hypothyroidism is scarce and controversial in the litera-
ture. A study on Bangladeshi pregnant women concluded
Table 2 Clinical features and maternal outcomes of hypothyroid pregnancies who had TSH measured before conception and









LSCS 131 (34.7) 134 (33.3) 148 (33.9) 168 (35.7)
Instrumental 13 (3.77) 14 (3.5) 18 (4.1) 22 (4.7)
SVD 128 (37.10) 134 (33.3) 164 (37.5) 171 (36.3)
Pregnancy outcomes
Abortion 27 (7.16) 33 (8.2) 4 (0.9) N/A
Live Birth (Twins/Triplets) 344 (91.25) 355 (88.3) 422 (96.5) 471 (100)
Ectopic 1 (0.27) 4 (1.0) 0 (0) N/A
Termination of Pregnancy 1 (0.27) 5 (1.2) 5 (1.1) 0 (0)
Intrauterine Death/Stillbirth 4 (0.01) 5 (1.2) 6 (1.4) 0 (0)
Gestational Hypertension
Yes 34 (9.0) N/A 52 (11.9) 56 (11.9)
No 343 (91.0) 385 (88.1) 415 (88.1)
Pre-Eclampsia
Yes 10 (2.7) N/A 19 (4.3) 20 (4.2)
No 367 (97.3) 418 (95.7) 451 (95.8)
Postpartum Hemorrhage
Yes 151 (40.1) N/A 178 (40.7) 204 (43.3)
No 226 (59.9) 259 (59.3) 267 (56.7)
Placental abruption
No 377 (100) N/A 437 (100) 1 (0.2)
Yes 0 (0) 0 (0) 470 (99.8)
TSH Thyroid stimulating Hormone. N/A not applicable. LSCS Lower segment Caesarean section. Em-LSCS emergency Lower segment Caesarean section. SVD
Spontaneous vaginal delivery
aPost medical treatment for Grave’s disease, Post-Radioactive Iodine Ablation and Post-Surgical
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Table 3 Comparison of baseline characteristics and maternal outcomes of controlled and uncontrolled hypothyroid patients before
conception
CLINICAL CHARACTERISTICS TSH PRECONCEPTION P -value
Controlled




mIU/L) N = 207
N (%) N (%)
Age (years)
18–25 15 (3.98) 16 (4.24) 0.43a
26–33 104 (27.59) 117 (31.03)
34–40 50 (13.26) 69 (18.30)
41–47 1 (0.27) 5 (1.33)
Parity
Nulliparous 42 (11.29) 54 (14.52) 0.8
Multiparous 125 (33.60) 151 (40.59)
Body Mass Index (Kg/m2)
Underweight (< 18.5) 7 (2.06) 6 (1.77) 0.2
Normal (18.5–24.9) 45 (13.27) 54 (15.93)
Overweight (25–29.9) 56 (16.52) 60 (17.70)
Obesity class I (30–34.9) 31 (9.14) 57 (16.81)
Obesity class II and above (> = 35) 13 (3.83) 10 (2.95)
Etiology of Hypothyroidism
Autoimmune 163 (43.35) 199 (52.93) 0.7
Post treatment$ 7 (1.86) 7 (1.86)
Thyroid antibodies
Positive 54 (36.99) 60 (41.10) 0.7
Negative 14 (9.59) 18 (12.33)
COMORBIDITIES
Diabetes Mellitus
Yes 10 (2.65) 18 (4.77) 0.3
No 160 (42.44) 189 (50.13)
Gestational diabetes mellitus
Yes 38 (10.08) 44 (11.67)
No 132 (35.01) 163 (43.24) 0.8
Hypertension
Normotensive 151 (40.05) 176 (46.68)
Previous Gestational Hypertension/Chronic Hypertension 19 (5.04) 31 (8.22) 0.3
MATERNAL OUTCOMES
Mode of labor (for live births only)
Spontaneous 29 (14.50) 37 (18.50) 0.24
Induced 45 (22.50)
Augmented 27 (13.50) 44 (22.00)
Not applicable due to Caesarean section 18 (9.00)
Mode of delivery (for live births only)
LSCS 80 (23.19) 124 (35.94) 0.012
Instrumental 7 (2.03) 6 (1.74)
SVD 71 (20.58) 57 (16.52)
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that cases with overt hypothyroidism were prone to have
gestational hypertension (GH) (42.9%) and gestational dia-
betes (38.1%) as compared to subclinical cases. A study on
more than 5000 pregnancies from Finland reported that
overt hypothyroidism predicts the risk of developing dia-
betes later [hazard ratio (HR) 6.0 (95% confidence inter-
val) (2.2–16.4)] [44]. In our population, gestational
diabetes was present in 21.2% cases and GH was only
10.6%. We need more prospective longitudinal studies to
analyze this difference from our center.
In our study Subclinical hypothyroidism was present in
around 37% of our total hypothyroid pregnant cases. A
retrospective cohort study based on 500 pregnant women in
the Indian city of Chennai conducted in 2007, reported 2.8%
subclinical hypothyroidism [43], and a prospective study
from Iran reported 11.3% of subclinical hypothyroidism
whereas clinical hypothyroidism was present in 2.4% preg-
nant females amongst 600 women with singleton pregnan-
cies [45]. A large study from the United Kingdom (UK)
database reported 7.4% subclinical hypothyroidism in
women already on levothyroxine replacement, with in-
creased risk of miscarriages as TSH rises above 2.5 uIU/mL
[46]. We also observed 14% overt hypothyroidism in our
study. A cross-sectional multicentre study of different states
of India reported an overall 36.07% prevalence of
hypothyroidism in pregnancy according to ATA cut-offs [7].
Although we could not classify a substantial number of pa-
tients as overt or subclinical in our population of 708
hypothyroid pregnancies, amongst those clearly labeled, it
consisted mainly of subclinical hypothyroidism.
Most of the findings on maternal outcomes from our
study are consistent with that conducted in other parts
of the world [13, 45]. Our study demonstrates that
TSH > 2.5 uIU/mL does not have a significant relation-
ship with abortions or any cause of pregnancy loss (p-
value 0.9 for preconception TSH and p values 0.12 & 0.8
for 1st and 2nd trimester TSH respectively), similar to
some recently published studies [47, 48]. On the other
hand, there is a significant relationship between precon-
ception TSH > 2.5 uIU/mL with cesarean section in our
cohort (p-value 0.047), which is different from a small
retrospective analysis of 167 pregnancies in the UK [1].
Although the overall C-section rate remained high in
their study cohort compared to the hospital as well as
the total UK C-section rate. This is in contrast to a study
from China where preconception TSH > 2.5 uIU/mL is
associated with adverse pregnancy outcomes including
cesarean section rate (aOR: 1·15, 95% CI: 1·10–1·22)
[49]. GH (p-value 0.4) and pre-eclampsia (p-value 0.19)
were not significantly associated in our patients with
preconception TSH > 2.5 uIU/mL. This is similar to a
case-control study conducted in India, where gestational
Table 3 Comparison of baseline characteristics and maternal outcomes of controlled and uncontrolled hypothyroid patients before
conception (Continued)
CLINICAL CHARACTERISTICS TSH PRECONCEPTION P -value
Controlled




mIU/L) N = 207
N (%) N (%)
Pregnancy outcomes
Abortion 12 (3.18) 15 (3.98) 0.9a
Live Birth (Twins/Triplets) 157 (41.64) 187 (49.60)
Ectopic 0 (0.00) 1 (0.27)
Termination of Pregnancy 0 (0.00) 1 (0.27)
Intrauterine Death/Stillbirth 1 (0.27) 3 (0.80)
Gestational Hypertension
Yes 13 (7.6) 21 (10.1) 0.4
No 157 (92.4) 186 (89.9)
Pre-Eclampsia
Yes 2 (1.2) 8 (3.9) 0.19a
No 168 (98.8) 199 (96.1)
Postpartum Hemorrhage
Yes 56 (32.9) 95 (45.9) 0.01
No 114 (67.1) 112 (54.1)
aFischer’s Exact
$Post medical treatment for Grave’s disease, Post-Radioactive Iodine Ablation and Post-Surgical
LSCS Lower segment Caesarean section. SVD Spontaneous vaginal delivery
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hypertension and pre-eclampsia were not associated with
hypothyroidism, although their TSH cutoff was between
3.1–6.2 uIU/mL [50] and a population-based prospective
data from Finland also reports no significant association
[subclinical hypothyroidism 20/213 (9.4%), p-value
0.615, HR 1.1 (0.7–1.7), Adjusted HR 1.0 (0.7–1.6)] [44].
In our study, postpartum hemorrhage was significantly
associated with hypothyroidism (p-value 0.01 in precon-
ception and 0.03 in 3rd trimester), however, this is less
well reported in the literature [32, 51] and need multiple
prospective case-control studies in our setup. In a
Turkish study, which was conducted on a well-defined
number of patients, taking into account several factors for
the cause of bleeding, no difference was found in terms of
coagulation parameters and PPH between euthyroid, sub-
clinical hypothyroid and healthy controls [52].
Internationally defined controlled levels of TSH (≤ 2.5
uIU/mL) during each trimester did not show significant
association with the outcomes in our study except for
mode of delivery (cesarean section) in preconception
and postpartum hemorrhage in the preconception and
third trimester. We need to analyze whether the absence
of availability of trimester-specific TSH ranges in our re-
gion is the reason behind this result and this demands a
large scale population based study of all pregnant
women in our country.
There are several limitations to our study, the most
important being that it was a retrospective analysis with
TSH levels not measured according to general recom-
mendations, despite an adequate diagnosis and levothyr-
oxine replacement timely initiated. Further, the results
of this study cannot be generalized to all pregnant popu-
lations as screening for thyroid dysfunction is not
universally performed and not all females with
hypothyroidism would have attended the antenatal clinic
despite an early miscarriage. Similarly, the autoimmune
status of the pregnant population need to be assessed
through population-based studies as anti-TPO anti-
bodies are not routinely measured in our setting. This
study, however, can be regarded as a baseline reflection
of our hypothyroid pregnant population. Moreover, this
is the only study with a large number of patients (708)
from Pakistan. We therefore recommend, large pro-
spective and multicentre, studies to assess the strength
of associations between maternal hypothyroidism and
outcome variables which may contribute towards unify-
ing universal screening and follow up management of
hypothyroid pregnancies.
Conclusion
The important findings of this study were excessive
post-partum hemorrhage and elective as well as
Table 4 Univariate analysis of maternal outcomes between TSH groups in 1st, 2nd and 3rd trimesters





















mIU/L) N = 215
P -value









Yes 22 (9.6) 30 (14.5) 25 (9.8) 31 (14.4) 0.12
No 208 (90.4) 177 (85.5) 231 (90.2) 184 (85.6)
Pre-Eclampsia N/A N/A 0.35 0.08
Yes 12 (5.2) 7 (3.4) 7 (2.7) 13 (6.0)
No 218 (94.8) 200 (96.6) 249 (97.3) 202 (94.0)
Postpartum
Hemorrhage
N/A N/A 0.09 0.03
Yes 85 (37) 93 (44.9) 99 (38.7) 105 (48.8)
No 145 (63) 114 (55.1) 157 (61.3) 110 (51.2)
Placental abruption N/A N/A – 0.5 a
No 230 (100) 207 (100) 256 (100) 214 (99.5)
Yes 0 (0) 0 (0) 0 (0) 1 (0.5)
TOP Termination of pregnancy
aFischer’s Exact
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emergency C-sections. Postpartum hemorrhage had a
significant association with uncontrolled TSH before
conception and in the third trimester. Moreover, this
study observed more subclinical hypothyroidism in the
peri-gestational period, which poses a great potential of
adversely affecting maternal outcomes.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12884-019-2596-9.
Additional file 1: Figure S1. Schematic division of controlled and
uncontrolled TSH groups in preconception and gestational periods. TSH
units in mIU/L
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